A5019086598- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- Neutropenia and Cancer Infections
- Hematological disorders and diagnostics
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Fungal Infections and Studies
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Hemoglobinopathies and Related Disorders
- HIV/AIDS drug development and treatment
- Antifungal resistance and susceptibility
- Immunodeficiency and Autoimmune Disorders
- Macrophage Migration Inhibitory Factor
- Cancer-related gene regulation
- Blood disorders and treatments
- Immune Cell Function and Interaction
Hospital Universitario Virgen del Rocío
2015-2024
Instituto de Biomedicina de Sevilla
2014-2024
Universidad de Sevilla
2013-2024
Fundación Pethema
2019
Consejo Superior de Investigaciones Científicas
2014-2015
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 SMAD3 signaling, showed promising results phase 2 study.In double-blind, placebo-controlled, 3 trial, we randomly assigned patients very-low-risk, low-risk, or intermediate-risk (defined according...
Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia thrombocytopenia.Patients were randomly assigned 1:1 to 300-mg or placebo 21 days/28-day cycle. The primary end point was transfusion independence (TI).Two hundred sixteen received (n = 107) 109). median age 74...
Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients AML myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading poor response prognosis. More than one-half of all (≥65 years) in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. We compared clinical outcomes for AML-MRC treated azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose...
a b s t r c tWe investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia 20-30% bone marrow blasts.Patients were treated azacitidine, one three dosage regimens: for 5 days (AZA 5); 7 including 2-day break 5-2-2); 7); all 28-day cycles.Overall response rates 39.4%, 67.9%, 51.3%, respectively, median overall survival (OS) durations 13.2, 19.1, 14.9 months.Neutropenia was most common...
Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation azacitidine promising clinical activity in AML Phase I studies. III, randomized, double-blind, placebo-controlled QUAZAR Maintenance trial (CC-486-AML-001) examines maintenance therapy (300 mg/day for 14 days 28-day treatment cycles) aged ≥55 years first remission. primary end point survival....
Background The number of CD34+ cells mobilized from bone marrow to peripheral blood after administration granulocyte colony-stimulating factor varies greatly among healthy donors. This fact might be explained, at least in part, by constitutional differences genes involved the interactions tethering marrow.Design and Methods We analyzed genetic characteristics associated with cell mobilization 112 individuals receiving (filgrastim; 10 μg/kg; 5 days).Results Genetic variants VCAM1 CD44 were...
Background Giving antifungal therapy exclusively to selected patients with persistent febrile neutropenia may avoid over-treatment without increasing mortality. The aim of this study was validate an innovative diagnostic and therapeutic approach based on assessing patients' risk profile clinical criteria in order select those requiring therapy. efficacy compared that universal empirical therapy.Design Methods This a prospective which included all consecutive adult hematology fever refractory...
BACKGROUND Options to treat elderly patients (≥65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy, hypomethylating agents or without venetoclax, supportive care. This multicenter, randomized, open‐label, phase 3 trial was designed assess the efficacy safety of a fludarabine, cytarabine, filgrastim (FLUGA) regimen in comparison azacitidine (AZA). METHODS Patients (n = 283) were randomized 1:1 FLUGA 141) AZA 142). Response evaluated...
Acute erythroleukemia (AEL) is a rare disease typically associated with poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong in patients myelodysplastic syndromes (MDS) and AML, but there limited data of their efficacy AEL. We collected 210 AEL treated at 28 international sites. Overall (OS) PFS were estimated using the Kaplan-Meier method log-rank test was used for subgroup comparisons. Survival...
Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and Leukemia Foundation (LRF) developed a score for older AML patients receiving IC non-intensive regimens, whereas E-ALMA study validated response elderly daily practice. Both identified three groups with different risk estimates. This analysis evaluates efficacy of frontline (N = 710) unfit from national...
Summary The impact of lenalidomide treatment on long‐term outcomes patients with lower risk myelodysplastic syndromes ( MDS ) and chromosome 5q deletion (del(5q)) is unclear. This study used time‐dependent multivariate methodology to analyse the influence therapy overall survival OS acute myeloblastic leukaemia AML progression in 215 International Prognostic Scoring System IPSS low or intermediate‐1 del(5q). There were significant differences several relevant characteristics at presentation...
In this prospective trial, the efficacy of azacitidine in lower-risk myelodysplastic syndromes (LR-SMD) lacking del(5q) was compared to best supportive care (BSC) at 1:1. The primary endpoint achievement erythroid hematologic improvement (HI-E) after nine cycles. Thirty-six patients received least ≥1 cycle. HI-E confirmed 44.4% randomized Aza and 5.5% receiving BSC (p < .01). After entry extension period, transfusion independence achieved all responders with a median duration 50 weeks...
New approaches of empirical antifungal therapy (EAT) in selected hematological patients with persistent febrile neutropenia (PFN) have been proposed recent years, but their cost-effectiveness has not studied. The aim this study was to compare the two different EAT PFN: diagnosis-driven (DDAT) approach versus standard EAT. A decision tree assess both developed. Outcome probabilities and treatment pathways were extrapolated from studies: a prospective cohort following DDAT randomized clinical...
Background High‐dose chemotherapy supported by autologous stem cell transplantation ( ASCT ) is an effective treatment for patients with lymphomas. However, failure to reach the minimum threshold of hematopoietic cells proceed may occur, even most strategies currently available. Study Design and Methods We report on 33 diagnosed lymphoma who had at least one prior mobilization received cytarabine a dose 400 mg/m 2 /day intravenously × 3 days plus granulocyte–colony‐stimulating factor G ‐ CSF...